Free Articles
Free to read — no membership required.
I Have APOE4. What Do I Do Now?
Written for someone who has just received an APOE4 result and does not yet know what it means — what the genotype does, what it does not, and the actions that have evidence behind them.
What APOE4 Means: A Practical Guide for Patients
What carrying one or two copies of APOE ε4 means for your brain, your risk, and the decisions in front of you — in plain language.
APOE 2, 3, and 4: What the Three Versions of This Gene Actually Do
Three versions of one gene, separated by two amino acids — and why that small difference sends Alzheimer’s risk in three different directions.
APOE ε4 Risk Is Not the Same in Every Population
The widely quoted risk figures come almost entirely from people of European ancestry. How much the numbers change elsewhere, and the haplotype explanation for why.
DHA and Brain Health: A Guide for APOE ε4 Carriers
Timing and molecular form both matter. What the DHA trials show for carriers before symptoms begin, and what they show after.
APOE ε4 or ApoE4? A Clinician’s Guide to Correct Nomenclature
Gene, allele, protein isoform, and search term are four different things. A short reference for using each correctly in writing and in clinic.
Stem Cells, Exosomes, and Peptides for Alzheimer’s Disease: What the Evidence Shows
A clinical review of regenerative therapies marketed to APOE ε4 carriers — what randomized evidence actually supports, and where it doesn’t.
The End of Alzheimer’s Program: A Neurologist’s Review
A board-certified neurologist and APOE ε4 carrier reviews Dale Bredesen’s bestselling protocol — what the evidence supports, and where it overclaims.
No More Sleepless Nights: A Neurologist’s Review
A physician’s review of a popular sleep program, and what the evidence actually says about sleep and APOE ε4 risk.
Why Some Scientists Question the Amyloid Hypothesis
Why the leading theory of Alzheimer’s disease is being challenged — and why it doesn’t change what APOE ε4 carriers should do.
Alzheimer’s Treatments and Emerging Therapies: A Guide for APOE ε4 Carriers
Current FDA-approved therapies, what’s in clinical trials, and what APOE ε4 status means for treatment candidacy.
Navigating Pre-Death Grief: Managing the Emotional Toll of Dementia Caregiving
The grief that begins long before the death does — why it is so often unrecognized, and what helps caregivers carry it.
Key Considerations After a Dementia Diagnosis in APOE ε4 Carriers
The decisions that matter most in the first months after a diagnosis, and the ones that can safely wait.
Who Helps After a Dementia Diagnosis? Building Your Care Team
Who belongs on the care team after a dementia diagnosis — and how to actually find a geriatric psychiatrist or social worker.
Intermittent Fasting: A Patient Guide
What intermittent fasting has been shown to do for brain aging, what remains mechanistic only, and who should not attempt it.
APOE ε4 Carriers and Meat
Dietary meat intake and cognitive outcomes in APOE ε4 carriers, and what the observational data can and cannot establish.
Member-Only Articles
Full clinical reviews and evidence tables. Become a member to unlock the complete library.
-
Armodafinil vs. Orexin Antagonists in APOE4 Carriers: Two Opposite Hypotheses, Only One With Real Support
Two opposing pharmacological hypotheses have been advanced for APOE4 carriers: wake-promoting agents such as armodafinil, versus dual orexin…
-
Change Your Brain Every Day (Amen, 2023): A Critical Appraisal for Clinicians Advising APOE ε4 Carriers
Amen’s daily reader recommends a lifestyle framework and a nine-supplement regimen in the same register. Only one survives…
-
The 2024 Alzheimer’s Diagnostic and Staging Criteria: What They Mean for APOE ε4 Carriers
The revised criteria redefine Alzheimer’s disease as a biological entity identified by biomarkers rather than by symptoms alone.…
-
What’s Good for the Heart Really Is Good for the Brain — But Know Your Genotype
Cardiovascular risk factors are among the most consistently modifiable contributors to dementia risk, but the magnitude of benefit…
-
Sleep and Cognitive Health in APOE ε4 Carriers
Sleep is among the few modifiable factors with a direct mechanistic link to Alzheimer’s pathology, including glymphatic clearance…
-
ARIA-E After Donanemab in an APOE ε4 Carrier: Risk Stratification, Management, and Rechallenge Considerations
Clinical Case Vignette — Anti-Amyloid Therapy ARIA-E After Donanemab in an APOE ε4 Carrier: Risk Stratification, Management, and…
-
Anti-Amyloid Therapy Candidacy in an APOE ε4 Heterozygote with Prior Microhemorrhages
Anti-Amyloid Therapy Candidacy in APOE ε4 Heterozygotes with Prior Microhemorrhages | ApoE4 Insights Clinical Content — For Licensed…
-
APOE ε4 Carrier, Pre-Symptomatic: Evidence-Based Management
Evidence-Based Review APOE ε4 · Pre-Symptomatic 2026 · Peer-Reviewed Synthesis APOE ε4 Carrier: Pre-SymptomaticEvidence-Based Management What to do…
-
The APOE4 Carrier and the Nutrition Dilemma
A critical appraisal of the SNAC-K cohort analysis (JAMA Network Open, 2026; n=2,157) reporting that higher meat intake…